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Abstract
Background/Aims: Insulin resistance (IR) plays an important role in the pathogenesis of diabetes and non-alcoholic 
fatty liver disease (NAFLD). Current methods for insulin resistance detection are cumbersome, or not sensitive enough 
for early detection and follow-up. The BreathID® system can continuously analyse breath samples in real-time at the 
point-of-care. Here we determined the efficacy of the BreathID® using the 13C-Glucose breath test (GBT) for evaluation 
of insulin resistance.
Methods: Twenty healthy volunteers were orally administered 75 mg of 13C-glucose 1-13C. An oral glucose tolerance 
test (OGTT) was performed immediately; followed by serum glucose and insulin level determinations using GBT. GBT 
and OGTT were repeated following exercise, which alters insulin resistance levels.
Results: Within-subject correlations of GBT parameters with serum glucose and serum insulin levels were high. Before 
and after exercise, between-subjects correlations were high between the relative insulin levels and the % dose 
recoveries at 90 min (PDR 90), and the cumulative PDRs at 60 min (CPDR 60). Pairwise correlations were identified 
between pre-exercise Homeostasis Model Assessment (HOMA) IR at 90 min and PDR 90; HOMA B (for beta cell 
function) 120 and CPDR 30; HOMA IR 60 and peak time post-exercise; and HOMA B 150 with PDR 150.
Conclusions: The non-invasive real-time BreathID® GBT reliably assesses changes in liver glucose metabolism, and the 
degree of insulin resistance. It may serve as a non-invasive tool for early diagnosis and follow up of patients in high-risk 
groups.
Introduction
Insulin resistance (IR) is defined as a subnormal response
to both endogenous and exogenous insulin [1]. It is char-
acterized by decreasing sensitivity of target tissues to the
action of insulin, by elevated blood glucose concentra-
tion, and increased hepatic production of atherogenic lip-
ids[2,3]. Insulin resistance contributes to the
pathophysiology of diabetes, and is a hallmark of obesity,
metabolic syndrome, and many cardiovascular diseases
[4-14]. Obesity, mainly of the abdominal type, is associ-
ated with resistance to the effects of insulin on peripheral
glucose and fatty acid utilization, often leading to type 2
diabetes mellitus [3,15-17].
Quantifying insulin sensitivity/resistance in humans
and animal models is important for basic and clinical sci-
ence, and eventually for clinical practice [6]. Direct and
indirect methods of varying complexity are currently
employed. Some rely on steady-state analysis of glucose
and insulin, while others rely on dynamic testing [6]. Each
of these methods has distinct advantages and limitations.
There is no consensus on when or how to evaluate
patients at risk for altered insulin resistance. In a clinical
setting, it would be useful to identify obese patients who
are insulin resistant prior to development of overt diabe-
tes. This group is at the highest risk for developing type 2
diabetes mellitus, cardiovascular disease, and non-alco-
holic fatty liver disease.
Breath testing is based on the principal that an ingested
substrate is metabolized, and a measurable metabolite is
then expelled by the respiratory system. Breath testing
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has been used experimentally and clinically for several
decades [12], including for follow-up on patients with
chronic liver disorders. The major drawbacks of these
tests are: the need for traditional, cumbersome isotopic
ratio mass spectrometry methods, a prolonged testing
time, high cost, and patient inconvenience. The BreathID®
continuous online 13C-methacetin breath test (MBT),
which reflects hepatic microsomal function (CYP1A2), is
a laser-based technology that creates an infrared emis-
sion precisely matching the absorption spectrum of CO2.
MBT can detect variations of less than 1/1000 in the
13CO2/12CO2  ratio measurement,18  measuring CO2  by
molecular correlation spectroscopy. This test offers sev-
eral advantages. It is an office-based, non-invasive tool
for the assessment of substrate metabolism. It does not
involve a blood test, and it can provide immediate results
at the point-of-care [18].
The aim of the present study was to determine the effi-
cacy of the BreathID® using the 13C-Glucose breath test
(GBT) as a tool for evaluation of insulin resistance.
Methods
Healthy Volunteers
Twenty healthy volunteers were enrolled in the study.
There were 11 males and 9 females with a mean age of
24.85 yr (19-33 yr), mean body mass index (BMI) of 27.04
(19.89-38.74), mean waist circumference of 92.5 cm (61-
121 cm), mean weight of 80.07 kg (49-121), and mean
height of 171.31 cm (159-188 cm). All participants were
screened by medical history and physical examination.
None had a history of active or previous diabetes, liver
disease, or alcohol or drug abuse, or were taking medica-
tions. All participants gave written informed consent to
their participation in the study, which was conducted in
strict adherence to the principles of the Declaration of
Helsinki. The institutional Ethics Committee approved all
experiments.
Oral glucose tolerance test combined with non-invasive 
breath testing
Following an over-night (at least 8-hr) fast, all subjects
were connected to the breath-testing unit's BreathID® sys-
tem (Exalenz Bioscience Ltd., Modiin, Israel) via nasal
cannula (IDcircuit™) and were orally administered 75 mg
of 13C-glucose 1-13C (Isotec) dissolved in 150 mL of water
with 75 g glucose. Breath samples were collected simulta-
neously with follow up of serum glucose and insulin lev-
els (at 0, 30, 60, 90, 120, 150, and 180 min) using an
automatic breath sampling unit under continuous capno-
graphic control, for 180 minutes after the labelled sub-
strate was administered to the patient. The 13CO2/12CO2
ratios in the breath samples were frequently determined
and mapped on the screen (once every 2-3 min the
machine measured the 13CO2/12CO2 calculating the PDR
at the same point). During the test period, all volunteers
continued fasting and were at rest, to eliminate any vari-
ability in CO2 excretion due to the ingestion of food or
physical activity.
Analysis of breath-test data
Results obtained from the device were expressed as per-
centage dose recovered (PDR-expresses the rate of sub-
strate metabolism) of administered 13C [%/h], cumulative
percentage dose of 13C recovered (CPDR-area under the
curve) [%] over time (at 0, 30, 60, 90, 120, 150, and 180
min after ingestion of labelled glucose), PDR peak, and
the time to peak. The change in the 13C/12C ratio takes
the specific test details into account, normalizing the
results, and making them independent of differences in
weight, height, dose, or substrate type and purity[14,15].
CPDR is the numeric integral of PDR and describes the
total amount of substrate metabolized at any given time.
Data are expressed in units of %/hr for PDR, and % for
CPDR. The BreathID® device plots the PDR and CPDR in
real time, and provides PDR peak value and peak time.
Determining the sensitivity of the test for detection of 
insulin resistance
We used exercise to assess the sensitivity of the GBT to
follow-up changes in insulin resistance. Both oral GTT
and the GBT were repeated before and after physical
exercise (30 min of walking at 6 km/hr). Subjects were
followed for 13CO2/12CO2 ratios, and serum glucose and
insulin levels (at 0, 30, 60, 90, 120, 150, and 180 min).
Statistical analysis
The comparison of two independent groups used Stu-
dent's t test, and the non-parametric Mann-Whitney test.
The association between two variables was assessed by
calculating the Pearson and the Spearman correlation
coefficients. Calculations of the within-subjects correla-
tion coefficients between each pair over all subjects were
derived from an analysis of variance table in a General
Linear Model, or from the within-cell correlations in
M u l t i v a r i a t e  A n a l y s i s  o f  V a r i a n c e  ( A N O V A ) .  A l l  t e s t s
were two-tailed, and a p value of 0.05 or less was consid-
ered statistically significant.
HOMA score
The Homeostasis Model Assessment (HOMA) is
designed to predict the homeostatic concentrations of
fasting insulin and glucose, which arise from varying
degrees of beta-cell deficiency and insulin resistance. The
model is nonlinear, but can be simply approximated. Two
types of HOMA scores are currently being evaluated in
clinical practice for determining fasting glucose and insu-
lin levels. HOMA IR = insulin resistance = (fasting insulinMizrahi et al. Nutrition Journal 2010, 9:25
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in mU/L) × (fasting plasma glucose in mmol/L)/22.5.
HOMA B = beta-cell function [%] = 20 × (fasting insulin
in mU/L)/((fasting glucose in mmol/L) - 3.5). We calcu-
lated the two types of HOMA scores following glucose
ingestion at 0, 30, 60, 90, 120, 150, and 180 min.
QUICKI score
The quantitative insulin sensitivity check index
(QUICKI) correlates well with the hyperinsulinemic eug-
lycemic clamp technique. The inverse of QUICKI is the
insulin resistance index, which is a good indirect measure
of insulin resistance. We calculated the QUICKI score for
serum glucose and insulin levels 0, 30, 60, 90, 120, 150,
and 180 min following glucose ingestion, using the fol-
lowing formulas: QUICKI = 1/(log10 ((fasting insulin in
ÂμU/mL) × (fasting plasma glucose in mg/dL))) = 1/
(log10 (fasting insulin in ÂμU/mL) + log10 (fasting plasma
glucose in mg/dL)). Insulin resistance index (IR) = log10
(fasting insulin) + log10 (fasting plasma glucose) = 1/
(QUICKI).
Results
Glucose breath test correlates with serum glucose levels
We found a high correlation between GBT parameters
and serum glucose levels. Fig. 1A shows the negative cor-
relation between glucose levels in the OGGT test and the
PDR (r = 0.935) before exercise, in a patient with a BMI >
30. Physical exercise is known to improve the degree of
insulin resistance, and was used in the present study to
assess the sensitivity of the GBT for changes in the degree
of insulin resistance. Alterations in the degree of IR post
exercise were detected by the GBT. Fig. 1B shows the neg-
ative correlation between glucose levels in the OGGT test
and the PDR (r = 0.916) after exercise in this patient.
Similar correlations were found for patients with BMIs
< 30. Fig. 1C shows a high negative correlation between
glucose levels in the OGGT test and the PDR (r = 0.887)
before exercise in a patient with a BMI < 30. Fig. 1D
shows the negative correlation between glucose levels in
the OGGT test and the PDR (r = 0.870) after exercise in a
patient with BMI < 30.
Like the PDR, the CPDR, the cumulative percentage
dose of 13C recovered over time, negatively correlated
with glucose levels. Fig. 2A shows the negative correla-
tion between glucose levels and the CPDR ratio (r =
0.813) in a patient with a BMI > 30. Fig. 2B shows the neg-
ative correlation between glucose levels and the CPDR
ratio (r = 0.813) in a patient with a BMI > 30.
Glucose breath test correlates with serum insulin levels
We found a high negative correlation between GBT
parameters and serum insulin levels. Fig. 3A shows the
negative correlation in the OGGT test before exercise
between insulin levels and the PDR (r = 0.678) in a patient
with a BMI > 30. A high negative correlation with insulin
levels was also noted after exercise. Fig. 3B shows the
negative correlation between insulin levels and the PDR
rate (r = 0.864) in the OGGT test after exercise in this
patient.
Similar correlations were found in patients with BMI <
30. Fig. 3C shows the negative correlation between serum
insulin levels and the PDR (r = 0.792) in the OGGT test
before exercise in a patient with a BMI < 30. A similar
high negative correlation remained after exercise. Fig. 3D
shows the negative correlation between glucose level and
the PDR rate (r = 0.791) in the OGGT test after exercise
in this patient.
Like the PDR, the CPDR was negatively correlated with
serum insulin levels. Fig. 4A shows the negative correla-
tion between insulin levels and the CPDR ratio in a
patient with BMI > 30 (r = 0.871), while Fig. 4B, shows the
correlation in a patient with BMI < 30 (r = 0.795).
Determining the sensitivity of the GBT for assessment of 
insulin resistance
A high within-subject correlation between serum glucose
levels and GBT is shown in Table 1. High negative corre-
lations were noted for the PDR (r = -0.804, p < 0.001), and
for the CPDR (r = -0.686, p  < 0.001), Fig. 5A and 5B
respectively. Similarly, high within-subject negative cor-
relations between serum insulin levels and GBT were
found. High negative correlations were detected for PDR
(r = -0.701, p < 0.001) and for CPDR (r = -0.683, p <
0.001) fig. 5C and 5D respectively.
To further determine the sensitivity of the test, GBT
a n d  O G T T  w e r e  r e p e a t e d  f o l l o w i n g  p h y s i c a l  e x e r c i s e ,
which alters the level of insulin resistance. High within-
subject negative correlations of the GBT parameters with
serum glucose levels were found (PDR r = -0.757, p <
0.001; CPDR r = -0.715, p < 0.001) and with serum insulin
levels (PDR r = -0.709, p < 0.001; CPDR r = -0.636, p <
0.001).
High between-subjects correlations were found
between the insulin levels ratio and the PDR 90 ratio (r =
0.8, p < 0.001) before and after exercise, and between the
ratio of glucose levels and the CPDR 60 ratios (r = 0.92, p
< 0.001) before and after exercise.
This data suggests that the GBT may serve as a valid
tool for detection of mild alterations in insulin resistance.
Glucose breath test correlates with HOMA score
High negative correlations were found before exercise
between the HOMA IR and the PDR value (Fig 6A). At 90
min the correlation was the highest for HOMA IR(r = -
0.479,  p  < 0.032), and at 120 min, for HOMA B and
CPDR, 30 min (r = -0.472, p < 0.035). Similarly, negative
correlations between the HOMA IR at 60 min and peak
time post exercise (r = 0.50, p < 0.02), and between theMizrahi et al. Nutrition Journal 2010, 9:25
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Figure 1 Patients underwent oral glucose tolerance test and glucose breath test. Correlation between serum glucose levels in the oral glucose 
tolerance test and PDR in a patient with BMI > 30 (A) before exercise; (B) after exercise; and for a patient with BMI < 30 (C) before exercise; and (D) after 
exercise.
Figure 2 Correlations were calculated between glucose levels and CPDR in (A) a patient with BMI > 30; and (B) in a patient with BMI < 30. 
Each dot represents a point of time following oral administration of glucose.Mizrahi et al. Nutrition Journal 2010, 9:25
http://www.nutritionj.com/content/9/1/25
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Figure 3 Correlations between serum insulin levels and PDR in (A) a patient with BMI > 30 before exercise; and (B) after exercise; and (C) in 
a patient with BMI < 30 before exercise; and (D) after exercise.
Figure 4 Correlations between insulin levels and CPDR in (A) a patient with BMI > 30; and in (B) a patient with BMI < 30. Each dot represents 
a point of time following oral administration of glucose.Mizrahi et al. Nutrition Journal 2010, 9:25
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HOMA B at 150 min with the PDR at 150 min (r = -0.653,
p < 0.002) were identified.
Glucose breath test correlates with QUICKI score
High correlations were detected before exercise between
the QUICKI score and the PDR at 120 min (p < 0.032),
between the QUICKI score and the peak time (p < 0.05),
and post exercise between the PDR at 90 min and the
QUICKI (p < 0.05).
Correlations between the GBT and age, gender, and BMI
GBT data was analyzed as a function of age, gender, and
BMI, using multiple linear regressions. For the non-obese
(BMI < 30) subgroup (n = 14) post exercise peak time (the
time to get to the higher point of 13CO2/12CO2 ratio) was
the most significant variable (not shown).
Discussion
Our data suggest that the non-invasive real-time
BreathID® GBT reliably assesses changes in the liver glu-
cose metabolism, and may serve as a tool for determining
insulin resistance. High within-subject correlations
between serum glucose and GBT were detected. The
G B T  p a r a m e t e r s  h i g h l y  c o r r e l a t e d  w i t h  s e r u m  i n s u l i n
levels.
In order to assess the sensitivity of the GBT for detect-
ing insulin resistance, the study was performed in healthy
Table 1: Within-subject correlations between serum glucose and insulin levels, and GBT percentage dose recovery (PDR), 
and cumulative percentage dose recovery (CPDR) before and after exercise.
PDR - Glucose PDR - Insulin CPDR - Glucose CPDR - Insulin
R p R p R p R p
Before exercise -0.804 < 0.001 -0.701 < 0.001 -0.686 < 0.001 -0.683 < 0.001
After exercise -0.757 < 0.001 -0/709 < 0.001 -0.715 < 0.001 -0.636 < 0.001
Figure 5 Correlations between the median value of glucose levels for all patients together every 30 minutes during OGTT and PDR every 
30 min. in (A) and (B) for CPDR every 30 min; and correlations between the median value of insulin levels for all patients together every 30 minutes 
during OGTT and PDR every 30 min. (C); and (D) for CPDR every 30 min.Mizrahi et al. Nutrition Journal 2010, 9:25
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volunteers after exercise. Exercise is a key component for
the successful management of many obesity-related met-
abolic complications, including insulin resistance.19 Both
chronic and acute endurance exercise has an effect on
insulin action in obesity. Exercise-induced alterations in
fatty acid partitioning within muscle cells affect insulin
sensitivity [19]. GBT and OGTT were repeated following
physical exercise. High between-subjects correlations
were found between the insulin levels ratio and the PDR
90 ratio before and after exercise, and between the ratio
of glucose levels and the CPDR 60 ratio before and after
exercise. Correlations were identified before exercise
between the HOMA IR at 90 min and the PDR at 90 min,
and between the HOMA B at 120 min and the CPDR at
3 0  m i n .  C o r r e l a t i o n s  w e r e  i d e n t i f i e d  a f t e r  e x e r c i s e
between the HOMA IR at 60 min and the peak time, and
between the HOMA B at 150 min and the PDR at 150
min. This data suggests that the GBT may serve as a valid
tool for detection of mild alterations in insulin resistance.
Currently available methods for assessment of insulin
resistance are invasive and cumbersome, making them
impractical for use at the point-of-care. The gold stan-
dard diagnostic test for insulin resistance is the hyperin-
sulinemic-euglycemic clamp, but this method is
unsuitable for everyday clinical use. The hyperinsuline-
mic euglycemic clamp and the insulin suppression test,
which are both labour and time intensive, directly assess
insulin-mediated glucose utilization under steady-state
conditions [20,21]. The degree of insulin resistance is
inversely proportional to the glucose uptake by target tis-
sues during the procedure. A slightly less complex indi-
rect method relies on minimal model analysis of a
frequently sampled intravenous glucose tolerance test.
The insulin sensitivity test (IST) and the Insulin tolerance
test (ITT) measure the decline in serum glucose after an
IV bolus of regular insulin. They primarily assess the
insulin-stimulated uptake of glucose into skeletal muscle
[21-25]. ISI is calculated for fat-free body mass by divid-
ing the glucose disposal rate by the average plasma insu-
lin concentration [6].
Surrogate indices for insulin sensitivity/resistance,
including QUICKI, HOMA, 1/insulin, and Matusda
index, are all derived from blood insulin and glucose con-
centrations under fasting conditions (steady state) or
after an oral glucose load (dynamic) [6]. Their relatively
low sensitivity, the time required for their performance,
and patient inconvenience make them unlikely to become
point-of-care screening tests.
Oral glucose tolerance tests (OGTTs), are a mainstay
for assessing insulin sensitivity [21-25] in the non-inva-
sive diagnosis of impaired glucose tolerance (IGT) and
diabetes mellitus. A modified OGTT uses a 75 mg glu-
cose load and measures glucose and insulin at various
intervals over two to four hours. OGTT provides infor-
m a t i o n  o n  b e t a  c e l l  s e c r e t i o n  a n d  p e r i p h e r a l  i n s u l i n
action. Insulin sensitivity has been assessed by calculating
insulin area under the curve (AUCinsulin), by the AUCglu-
cose/AUCinsulin ratio, and by an insulin sensitivity index
(ISI) that uses glucose and insulin values from 0 and 180
min in a mathematical formula. A more qualitative
assessment of insulin resistance is the observation of one
or more insulin values exceeding an upper, normal, limit
at appropriate intervals [25].
The search for simple and inexpensive quantitative
tools to evaluate insulin sensitivity has led to develop-
ment of fasting state (homeostatic) assessments. These
tests are based on fasting glucose and fasting insulin, and
a calculation to assess insulin sensitivity and beta cell
function. The homeostasis model assessment (HOMA)
and quantitative insulin sensitivity check index (QUICKI)
have been devised, [3,6,22] and may be applied to normo-
glycemic and hyperglycemic patients. Fasting insulin (I0),
Figure 6 Correlations between the median value of HOMA IR for all patients together every 30 minutes during OGTT and PDR every 30 min. 
in (A) and (B) for CPDR and HOMA B every 30 min.Mizrahi et al. Nutrition Journal 2010, 9:25
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and the glucose/insulin (G/I) ratio are inexpensive assays
for calculations of insulin resistance [6]. We found a high
correlation between the QUICKI score and the PDR at
120 minutes (before exercise), peak time (before exer-
cise), and PDR 90 minutes (post exercise).
Homeostatic model assessment (HOMA) has been
widely employed in clinical research to assess insulin sen-
sitivity. Unlike the I0 and G/I ratio, HOMA calculations
compensate for fasting hyperglycemia [6]. HOMA values
correlate well with the results of clamp techniques, and
ha ve been frequently used to assess changes in insulin
sensitivity after treatment [26,27]. However, this model
assumes that beta cell function is normal and does not
apply to patients with type 2 diabetes. One of the weak-
nesses of these models is that they assume the relation-
ship between glucose and insulin is linear, when in fact
it's parabolic. Another weakness is that they assume that
beta cell function is normal and do not apply to patients
with type 2 diabetes. These indices of insulin resistance
necessitate serum insulin and glucose measurements,
may require complex calculations, and have not yet made
major inroads into general medical practice. None of
these can be performed at the point-of-care, and their
sensitivity varies over patient populations and BMIs.
Our pre exercise data shows high correlations between
HOMA IR 90 min and PDR 90. Our post exercise data
shows high correlations between HOMA B 120 and
CPDR 30 min, between HOMA IR 60 min and peak time
post exercise, and between HOMA B 150 min and PDR
150 min.
Previous studies suggested the use of GBT in patients
with diabetes [28]. A comparison of the 13C GBT using
mass spectrometry with the hyperinsulinemic-euglyce-
mic clamp to determine insulin resistance has been per-
formed, and suggests a high correlation between the
results of the two tests [28]. High correlations between
13C GBT parameters and glucose metabolism and insulin
sensitivity indices from insulin clamp measurements
were described. The magnitudes of these correlations
compared favourably with QUICKI and were superior to
the homeostasis model assessment. However, the use of
mass spectrometer in this setting is cumbersome and
does not enable the use of the test as a daily decision
making tool.
GBT using an office-based device offers several advan-
tages over the currently available techniques for assess-
ment of insulin resistance. It is a non-invasive, point-of-
care test. It is not operator dependent, and its sensitivity
seems higher than the currently used tests. Currently
available methods are either invasive, or not sensitive
enough to detect insulin resistance at early stages, or to
follow-up treatment. Target populations for screening
may include patients with metabolic syndrome, pregnant
women, patients with NAFLD, patients at early stages of
diabetes, and chronic HCV patients without overt diabe-
tes [29-34].
Although we studied a relative small population of sub-
jects, the data of the present study suggests that the GBT
can serve as a non-invasive tool for dynamic evaluation of
glucose metabolism, for early diagnosis and for follow-up
of patients in groups at high-risk of insulin resistance.
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